SMTL ID : 4uqh.1

Crystal structure of Trypanosoma cruzi CYP51 bound to the inhibitor (R)-N-(3-(1H-indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-4-(4-(3,4-difluorophenyl)piperazin-1-yl)-2-fluorobenzamide.

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.43 Å

Oligo State

homo-trimer

Ligands

3 x HEM: PROTOPORPHYRIN IX CONTAINING FE(Non-covalent)

HEM.1: 24 residues within 4Å: Chain A: F.70, Y.96, L.107, L.114, A.268, A.271, G.272, T.275, T.279, P.335, L.336, V.339, R.341, G.394, F.395, G.396, A.397, H.400, K.401, C.402, I.403, G.404, A.408 Ligands: 25S.9 13 PLIP interactions: 13 interactions with chain A, Hydrophobic interactions: A:L.107, A:L.114, A:A.271, A:P.335, A:F.395, A:I.403, A:A.408 Hydrogen bonds: A:Y.96, A:Y.96, A:A.397 Salt bridges: A:R.341, A:H.400 Metal complexes: A:C.402 HEM.10: 24 residues within 4Å: Chain B: F.70, Y.96, L.107, L.114, A.268, A.271, G.272, T.275, T.279, P.335, L.336, V.339, R.341, G.394, F.395, G.396, A.397, H.400, K.401, C.402, I.403, G.404, A.408 Ligands: 25S.18 13 PLIP interactions: 13 interactions with chain B, Hydrophobic interactions: B:L.107, B:L.114, B:A.271, B:P.335, B:F.395, B:I.403, B:A.408 Hydrogen bonds: B:Y.96, B:Y.96, B:A.397 Salt bridges: B:R.341, B:H.400 Metal complexes: B:C.402 HEM.19: 24 residues within 4Å: Chain C: F.70, Y.96, L.107, L.114, A.268, A.271, G.272, T.275, T.279, P.335, L.336, V.339, R.341, G.394, F.395, G.396, A.397, H.400, K.401, C.402, I.403, G.404, A.408 Ligands: 25S.27 13 PLIP interactions: 13 interactions with chain C, Hydrophobic interactions: C:L.107, C:L.114, C:A.271, C:P.335, C:F.395, C:I.403, C:A.408 Hydrogen bonds: C:Y.96, C:Y.96, C:A.397 Salt bridges: C:R.341, C:H.400 Metal complexes: C:C.402

21 x SO4: SULFATE ION(Non-functional Binders)

SO4.2: 5 residues within 4Å: Chain A: G.91, E.92, R.210, R.213, H.259 Ligand excluded by PLIP SO4.3: 6 residues within 4Å: Chain A: H.286, H.289, K.291, N.292, W.380, V.432 Ligand excluded by PLIP SO4.4: 5 residues within 4Å: Chain A: Q.120, V.123, P.124, N.311, Y.312 Ligand excluded by PLIP SO4.5: 2 residues within 4Å: Chain A: S.257, L.258 Ligand excluded by PLIP SO4.6: 4 residues within 4Å: Chain A: R.327, F.392, F.395, Q.405 Ligand excluded by PLIP SO4.7: 2 residues within 4Å: Chain A: E.386, D.389 Ligand excluded by PLIP SO4.8: 3 residues within 4Å: Chain A: E.65, R.68, G.350 Ligand excluded by PLIP SO4.11: 5 residues within 4Å: Chain B: G.91, E.92, R.210, R.213, H.259 Ligand excluded by PLIP SO4.12: 6 residues within 4Å: Chain B: H.286, H.289, K.291, N.292, W.380, V.432 Ligand excluded by PLIP SO4.13: 5 residues within 4Å: Chain B: Q.120, V.123, P.124, N.311, Y.312 Ligand excluded by PLIP SO4.14: 2 residues within 4Å: Chain B: S.257, L.258 Ligand excluded by PLIP SO4.15: 4 residues within 4Å: Chain B: R.327, F.392, F.395, Q.405 Ligand excluded by PLIP SO4.16: 2 residues within 4Å: Chain B: E.386, D.389 Ligand excluded by PLIP SO4.17: 3 residues within 4Å: Chain B: E.65, R.68, G.350 Ligand excluded by PLIP SO4.20: 5 residues within 4Å: Chain C: G.91, E.92, R.210, R.213, H.259 Ligand excluded by PLIP SO4.21: 6 residues within 4Å: Chain C: H.286, H.289, K.291, N.292, W.380, V.432 Ligand excluded by PLIP SO4.22: 5 residues within 4Å: Chain C: Q.120, V.123, P.124, N.311, Y.312 Ligand excluded by PLIP SO4.23: 2 residues within 4Å: Chain C: S.257, L.258 Ligand excluded by PLIP SO4.24: 4 residues within 4Å: Chain C: R.327, F.392, F.395, Q.405 Ligand excluded by PLIP SO4.25: 2 residues within 4Å: Chain C: E.386, D.389 Ligand excluded by PLIP SO4.26: 3 residues within 4Å: Chain C: E.65, R.68, G.350 Ligand excluded by PLIP

3 x 25S: (R)-N-(3-(1H-indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-4-(4-(3,4-difluorophenyl)piperazin-1-yl)-2-fluorobenzamide(Non-covalent)

25S.9: 17 residues within 4Å: Chain A: F.28, I.52, V.57, Y.83, I.85, M.86, F.90, Y.96, F.194, F.270, A.271, L.336, M.338, M.340, M.440, V.441 Ligands: HEM.1 8 PLIP interactions: 8 interactions with chain A Hydrophobic interactions: A:F.28, A:F.90, A:Y.96, A:F.270, A:A.271, A:M.440 pi-Stacking: A:Y.83, A:F.194 25S.18: 17 residues within 4Å: Chain B: F.28, I.52, V.57, Y.83, I.85, M.86, F.90, Y.96, F.194, F.270, A.271, L.336, M.338, M.340, M.440, V.441 Ligands: HEM.10 8 PLIP interactions: 8 interactions with chain B Hydrophobic interactions: B:F.28, B:F.90, B:Y.96, B:F.270, B:A.271, B:M.440 pi-Stacking: B:Y.83, B:F.194 25S.27: 17 residues within 4Å: Chain C: F.28, I.52, V.57, Y.83, I.85, M.86, F.90, Y.96, F.194, F.270, A.271, L.336, M.338, M.340, M.440, V.441 Ligands: HEM.19 8 PLIP interactions: 8 interactions with chain C Hydrophobic interactions: C:F.28, C:F.90, C:Y.96, C:F.270, C:A.271, C:M.440 pi-Stacking: C:Y.83, C:F.194

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Calvet, C.M. et al., 4-Aminopyridyl-Based Cyp51 Inhibitors as Anti-Trypanosoma Cruzi Drug Leads with Improved Pharmacokinetic Profile and in Vivo Potency. J.Med.Chem. (2014)

Release Date

2014-08-20

Peptides

STEROL 14-ALPHA DEMETHYLASE: ABC

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

B
A

C
A

STEROL 14-ALPHA DEMETHYLASE

Related Entries With Identical Sequence